SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer

Supernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer
EN
05/10/2020

Underlying

SUPNSupernus Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Supernus Pharmaceuticals Inc.

 PRESS RELEASE
Free
SUPN Supernus Pharma...

Supernus to Participate in the 2025 Jefferies Global Healthcare Confer...

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference in London on Monday, November 17, 2025, at 9:30 a.m. EST (2:30 p.m. GMT). Investors interested in arr...

2h / 8m 1 EN
 PRESS RELEASE
Free
SUPN Supernus Pharma...

Supernus Announces Third Quarter 2025 Financial Results

Supernus Announces Third Quarter 2025 Financial Results Combined revenues of the Company's four growth products increased 52% to $149.2 million in the third quarter of 2025, compared to the same period in 2024. This strong growth was driven by an increase in net sales of Qelbree® and GOCOVRI®, and the addition of sales from ZURZUVAE® and ONAPGO™.Total revenues were $192.1 million in the third quarter of 2025, a 9% increase compared to the same period in 2024.Completed the acquisition of Sage Therapeutics, Inc. (Sage) on July 31, 2025.Cash, cash equivalents and current marketable securities ...

November 4, 2025 1 EN
 PRESS RELEASE
Free
SUPN Supernus Pharma...

Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Resu...

Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 ROCKVILLE, Md., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report third quarter 2025 financial and business results after the market closes on Tuesday, November 4, 2025. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will ho...

October 21, 2025 1 EN
 PRESS RELEASE
Free
SUPN Supernus Pharma...

Supernus Pharmaceuticals to Participate in September Investor Conferen...

Supernus Pharmaceuticals to Participate in September Investor Conferences ROCKVILLE, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today management will participate in the following September investor conferences: Cantor Global Healthcare ConferenceDate:Fireside chat:Place:   Wednesday, September 3, 2025 8:00 a.m. ET New York Marriott Marquis, New York, NY   Wells Fargo Healthcare ConferenceDate:Firesid...

August 27, 2025 1 EN
 PRESS RELEASE
Free
SUPN Supernus Pharma...

Supernus Announces Second Quarter 2025 Financial Results

Supernus Announces Second Quarter 2025 Financial Results Net sales of Qelbree® increased 31% in the second quarter of 2025, compared to the same period in 2024. Net sales of Qelbree of $77.6 million and $142.3 million in the second quarter and first six months of 2025, respectively. Net sales of GOCOVRI® increased 16% in the second quarter of 2025, compared to the same period in 2024. Net sales of GOCOVRI of $36.7 million and $67.4 million in the second quarter and first six months of 2025, respectively. ONAPGO™ (apomorphine hydrochloride) launched in April 2025.Total revenues were $165.5 m...

August 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch